Olfactory dysfunction in LRRK2 G2019S mutation carriers

被引:51
|
作者
Saunders-Pullman, R. [1 ,2 ]
Stanley, K. [1 ]
Wang, C. [3 ]
San Luciano, M. [1 ]
Shanker, V. [1 ,2 ]
Hunt, A. [1 ]
Severt, L. [1 ]
Raymond, D. [1 ]
Ozelius, L. J. [4 ,5 ]
Lipton, R. B. [2 ]
Bressman, S. B. [1 ,2 ]
机构
[1] Beth Israel Deaconess Med Ctr, Dept Neurol, New York, NY 10003 USA
[2] Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467 USA
[3] Albert Einstein Coll Med, Dept Epidemiol & Social Med, Bronx, NY 10467 USA
[4] Mt Sinai Sch Med, Dept Genet, New York, NY USA
[5] Mt Sinai Sch Med, Dept Genom Sci & Neurol, New York, NY USA
关键词
FAMILIAL PARKINSONS-DISEASE; EARLY-ONSET; IDENTIFICATION; PATHOLOGY; HYPOSMIA; STAGE;
D O I
10.1212/WNL.0b013e318227041c
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Olfactory dysfunction is an established nonmotor feature of idiopathic Parkinson disease (PD), which may precede disease onset. Olfaction is likely disturbed in patients with PD with leucine-rich repeat kinase (LRRK2) G2019S mutations, although the degree of impairment is debated. It is also unclear whether mutation carriers who have not yet manifested with PD have olfactory disturbances. Methods: Thirty-one subjects with LRRK2 G2019S mutation-related PD (PD-manifesting carriers [PD-MC]), 30 subjects with PD without mutations (PD noncarriers [PD-NC]), 28 mutation carrier family members (nonmanifesting carriers [NMC]), and 46 controls completed the University of Pennsylvania Smell Identification Test (UPSIT). Generalized estimating equations were applied to determine whether olfactory score was associated with PD and LRRK2 mutation status. Results: As expected, having PD was associated with impaired olfaction regardless of LRRK2 mutation status. More importantly, however, impaired olfaction was increased overall in LRRK2 carriers both with and without PD, though the impairment was only present in a subset of NMCs. Compared to controls, the mean score was lower among NMC (difference = -3.518, p = 0.006), MC (difference = -7.677, p < 0.0001), and idiopathic PD (PD-NC) (difference = -13.810, p < 0.0001). Olfaction was better among MC (PD-MC) than non-LRRK2 PD (PD-NC) (difference = 6.13, p = 0.0012). Group differences from the continuous analysis were maintained in dichotomous analysis stratifying at 15th percentile for age and gender. Conclusion: Olfaction is impaired in LRRK2 G2019S-mutation related PD, although less overall than other PD. Further, olfaction is impaired in a subset of LRRK2 NMC, suggesting that olfaction may be a marker for development of PD in this group, and that longitudinal studies are warranted. Neurology (R) 2011; 77: 319-324
引用
收藏
页码:319 / 324
页数:6
相关论文
共 50 条
  • [21] Olfactory Deficits and Cardiac 123I-MIBG in Parkinson's Disease Related to the LRRK2 R1441G and G2019S Mutations
    Ruiz-Martinez, Javier
    Gorostidi, Ana
    Goyenechea, Estibaliz
    Alzualde, Ainhoa
    Jose Poza, Juan
    Rodriguez, Francisco
    Bergareche, Alberto
    Moreno, Fermin
    Lopez de Munain, Adolfo
    Marti Masso, Jose F.
    MOVEMENT DISORDERS, 2011, 26 (11) : 2026 - 2031
  • [22] Parkinson Disease Phenotype in Ashkenazi Jews With and Without LRRK2 G2019S Mutations
    Alcalay, Roy N.
    Mirelman, Anat
    Saunders-Pullman, Rachel
    Tang, Ming-X
    Mejia Santana, Helen
    Raymond, Deborah
    Roos, Ernest
    Orbe-Reilly, Martha
    Gurevich, Tanya
    Bar Shira, Anat
    Weisz, Mali Gana
    Yasinovsky, Kira
    Zalis, Maayan
    Thaler, Avner
    Deik, Andres
    Barrett, Matthew James
    Cabassa, Jose
    Groves, Mark
    Hunt, Ann L.
    Lubarr, Naomi
    San Luciano, Marta
    Miravite, Joan
    Palmese, Christina
    Sachdev, Rivka
    Sarva, Harini
    Severt, Lawrence
    Shanker, Vicki
    Swan, Matthew Carrington
    Soto-Valencia, Jeannie
    Johannes, Brooke
    Ortega, Robert
    Fahn, Stanley
    Cote, Lucien
    Waters, Cheryl
    Mazzoni, Pietro
    Ford, Blair
    Louis, Elan
    Levy, Oren
    Rosado, Llency
    Ruiz, Diana
    Dorovski, Tsvyatko
    Pauciulo, Michael
    Nichols, William
    Orr-Urtreger, Avi
    Ozelius, Laurie
    Clark, Lorraine
    Giladi, Nir
    Bressman, Susan
    Marder, Karen S.
    MOVEMENT DISORDERS, 2013, 28 (14) : 1966 - 1971
  • [23] G2019S selective LRRK2 kinase inhibitor abrogates mitochondrial DNA damage
    Pena, Nicholas
    Richbourg, Tara
    Gonzalez-Hunt, Claudia P.
    Qi, Rui
    Wren, Paul
    Barlow, Carrolee
    Shanks, Natalie F.
    Carlisle, Holly J.
    Sanders, Laurie H.
    NPJ PARKINSONS DISEASE, 2024, 10 (01)
  • [24] LRRK2 G2019S Mutations are Associated with an Increased Cancer Risk in Parkinson Disease
    Saunders-Pullman, Rachel
    Barrett, Matthew J.
    Stanley, Kaili M.
    San Luciano, Marta
    Shanker, Vicki
    Severt, Lawrence
    Hunt, Ann
    Raymond, Deborah
    Ozelius, Laurie J.
    Bressman, Susan B.
    MOVEMENT DISORDERS, 2010, 25 (15) : 2536 - 2541
  • [25] Parkinson's disease-related LRRK2 G2019S mutation results from independent mutational events in humans
    Lesage, Suzanne
    Patin, Etienne
    Condroyer, Christel
    Leutenegger, Anne-Louise
    Lohmann, Ebba
    Giladi, Nir
    Bar-Shira, Anat
    Belarbi, Soraya
    Hecham, Nassima
    Pollak, Pierre
    Ouvrard-Hernandez, Anne-Marie
    Bardien, Soraya
    Carr, Jonathan
    Benhassine, Traki
    Tomiyama, Hiroyuki
    Pirkevi, Caroline
    Hamadouche, Tarik
    Cazeneuve, Cecile
    Basak, A. Nazli
    Hattori, Nobutaka
    Duerr, Alexandra
    Tazir, Meriem
    Orr-Urtreger, Avi
    Quintana-Murci, Lluis
    Brice, Alexis
    HUMAN MOLECULAR GENETICS, 2010, 19 (10) : 1998 - 2004
  • [26] Olfactory Dysfunction in Parkinson's Disease Patients with the LRRK2 G2385R Variant
    Cao, Ming
    Gu, Zhu-Qin
    Li, Yuan
    Zhang, Hui
    Dan, Xiao-Juan
    Cen, Shan-Shan
    Li, Da-Wei
    Chan, Piu
    NEUROSCIENCE BULLETIN, 2016, 32 (06) : 572 - 576
  • [27] Genetic analysis and natural history of Parkinson's disease due to the LRRK2 G2019S variant
    Kmiecik, Matthew J.
    Micheletti, Steven
    Coker, Daniella
    Heilbron, Karl
    Shi, Jingchunzi
    Stagaman, Keaton
    Sonmez, Teresa Filshtein
    Fontanillas, Pierre
    Shringarpure, Suyash
    Wetzel, Madeleine
    Rowbotham, Helen M.
    Cannon, Paul
    Shelton, Janie F.
    Hinds, David A.
    Tung, Joyce Y.
    Holmes, Michael, V
    Aslibekyan, Stella
    Norcliffe-Kaufmann, Lucy
    BRAIN, 2024, 147 (06) : 1996 - 2008
  • [28] Subclinical signs in LRRK2 mutation carriers
    Johansen, Krisztina K.
    White, Linda R.
    Farrer, Matthew J.
    Aasly, Jan O.
    PARKINSONISM & RELATED DISORDERS, 2011, 17 (07) : 528 - 532
  • [29] Ashkenazi Parkinson's disease patients with the LRRK2 G2019S mutation share a common founder dating from the second to fifth centuries
    Bar-Shira, Anat
    Hutter, Carolyn M.
    Giladi, Nir
    Zabetian, Cyrus P.
    Orr-Urtreger, Avi
    NEUROGENETICS, 2009, 10 (04) : 355 - 358
  • [30] Association between Parkinson's disease and G2019S and R1441C mutations of the LRRK2 gene
    Li, Xiao-Xia
    Liao, Qin
    Xia, Huan
    Yang, Xin-Ling
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2015, 10 (04) : 1450 - 1454